content_image/274973.jpg content_image/274974.jpg
## Europe * , Middle East and Africa (EMEA) 

We will drive sustained growth by expanding the ur ology franchise and quickly establishing a business platform in the oncology field. 

* Includes NIS countries 

<img src='content_image/274973.jpg'>

<img src='content_image/274974.jpg'>

Note: Yen base *Calculated according to the location of sellers *IFRS 

Fiscal 2013 Overview *Sales and year-on-year changes are based on J-GAAP. Net sales in EMEA in fiscal 2013 grew 8.5% to € 1,990 million. When converted to yen, net sales rose 36.1% to ¥267.4 billion. 

By product, sales of Vesicare continued to show steady growth, up strongly by 13.0% on a euro basis. The new products BETMIGA and XTANDI contributed to increased sales. Furthermore, sales of MYCAMINE grew steadily. Sales of Omnic, which goes by the brand name Harnal in Japan, through our own distribution channel were mostly unchanged from the previous fiscal year. Meanwhile, although sales of Advagraf continued growing in EMEA, sales of Prograf (including the Advagraf formulation) through our own distribution channel recorded a 1.3% decline on a euro basis due to the impact of generic products. 

In terms of new products, we launched VESOMNI, a Vesicare/Omnic combination drug, in September 2013. 

Fiscal 2014 Outlook *Sales and year-on-year changes are based on IFRS. In fiscal 2014, we project an 11.0% increase in net sales in EMEA to € 2,183 million on a euro basis. This equates to ¥305.6 billion in yen terms, representing a 15.6% increase. Our forecast is based on ongoing growth in sales of XTANDI, as well as OAB treatments Vesicare and BETMIGA. Although sales of Prograf are forecast to decline on a euro basis, we expect the foreign exchange impact to result in higher sales for this product on a yen basis. 

